Research Paper Volume 13, Issue 6 pp 8665—8687

MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling

Activation of the PI3K/AKT pathway promoted DDP-resistant SGC7901 cell proliferation, invasion and migration through up-regulation of related neoplastic proteins (Bcl-xl and Bcl-2), EMT-related proteins and drug resistance-related proteins. (A, B) Transwell chamber assay indicated increased invasion and migration in the PI3K/AKT activator-treated group compared to the miR-95-3p inhibitor treated group. (C) Wound healing assay indicated that the PI3K/AKT activator significantly improved DDP-resistant SGC7901 cellular invasion. (D) Western blot results demonstrated that the use of a PI3K/AKT activator promoted oncogenic expression, and increase of EMT process-related proteins and drug resistance-related proteins. ***p

Figure 10. Activation of the PI3K/AKT pathway promoted DDP-resistant SGC7901 cell proliferation, invasion and migration through up-regulation of related neoplastic proteins (Bcl-xl and Bcl-2), EMT-related proteins and drug resistance-related proteins. (A, B) Transwell chamber assay indicated increased invasion and migration in the PI3K/AKT activator-treated group compared to the miR-95-3p inhibitor treated group. (C) Wound healing assay indicated that the PI3K/AKT activator significantly improved DDP-resistant SGC7901 cellular invasion. (D) Western blot results demonstrated that the use of a PI3K/AKT activator promoted oncogenic expression, and increase of EMT process-related proteins and drug resistance-related proteins. ***p<0.001, **p<0.01.